Skip to main content

Planned MS study will test scans to track worsening

By MS Buddy ·

Summarized from Neuroradiology, Nov 2026 · PubMed · DOI. AI-generated summary. Not medical advice.

127 people with relapsing-remitting MS (flare-ups followed by recovery) and healthy volunteers

Research by Lis van den Boogaard, Jacobus Jansen and 7 colleagues at the Eindhoven University of Technology in the Netherlands.

Can detailed brain scans help predict MS worsening without flare-ups?

Key Takeaway

This planned study will test whether scans of nerve covering can help explain MS worsening without flare-ups or new areas of damage.

Muted blue and clay ribbons curve across an off-white background, wrapped in soft layers of varying thickness.
Credibility
Interest
Share:1 min read

What They Found

The abstract describes a study plan, not completed results. Researchers will measure myelin (the protective covering around nerves) using detailed brain scans. They will compare people whose MS worsens with those whose MS does not worsen. Blood tests will look for signs of nerve damage and activity in cells that support nerves. The study aims to find scan signs that predict worsening without flare-ups or new areas of damage.

Who Should Care and Why

The study will include people with relapsing-remitting MS (MS with flare-ups followed by periods of recovery) and healthy volunteers. It focuses on worsening that can happen without flare-ups or new damage visible on standard scans. Researchers will study whether changes in nerve covering help explain this worsening. Healthy volunteers will have a single scan to provide a comparison. Participants with MS can also use a smartphone app to track changes in daily functioning.

Important Considerations

This is a planned study that will follow 97 people with MS over time and scan 30 healthy volunteers. The abstract provides no results showing whether these scans predict worsening. It does not show whether using these scans to guide care improves health.

AI-generated summary — for informational purposes only, not medical advice

Read the original abstract

Published in Neuroradiology by et al.. Reproduced from the PubMed record.

It is increasingly recognized that patients with relapsing-remitting multiple sclerosis (RRMS) may experience disability progression in the absence of clinical relapses and new lesions, a phenomenon known as progression independent of relapse- and magnetic resonance imaging (MRI) activity (PIRMA). The biological basis of this type of progression remains poorly understood. Demyelination is the central pathological hallmark of RRMS. Conventional clinical MRI protocols focus primarily on detecting focal lesions. However, advanced imaging techniques that quantify myelin content can provide additional insights beyond visible lesions, helping to better understand the mechanisms that drive clinical deterioration. Therefore, this study named IMPROving MYelin imaging in patients with relapsing-remitting Multiple Sclerosis (IMPROMYMS study) aims to apply myelin imaging techniques to study clinically defined disease progression in patients with RRMS, by assessing myelin content and comparing it to patients with RRMS without progression of the disease. In total, 97 patients with RRMS will be included and followed for 2.5 years. Participants will undergo MRI scanning at baseline and after 2 years and have regular clinical follow-up visits. Besides conventional MRI, advanced imaging sequences will be scanned, including gradient spin echo (GRASE), multi-echo gradient echo (ME-GRE), diffusion and functional MRI. Additionally, blood samples will be collected longitudinally to assess circulating biomarkers of neuroaxonal damage and astrocytic activation. Participants can also use the smartphone symptom-monitoring app MS Sherpa to enable more frequent monitoring of functional changes in daily life. In addition, 30 healthy controls will be scanned once as a reference group. In this study, we expect to find radiological prognostic markers of an increased risk of developing PIRMA, so that disease management strategies can be altered accordingly.

The app

Check out the MS Buddy app

It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play

Related MS research

Two cut-paper nerve shapes with interrupted wraps, one surrounded by fewer rust-colored clusters than the other.
Experimental drug eased MS-like disease signs in mice

11/17/2026

An experimental drug eased nerve-related problems and reduced inflammation in mice with an MS-like d

Read More
Soft gray-blue layers with scattered rust-colored flecks and gently fragmenting edges on an off-white background.
Review explores cell death in MS and other diseases

11/17/2026

A review explores iron-driven cell death in MS and other diseases involving immune attacks on the bo

Read More
Stem cells beside a nerve fiber with gaps in its myelin covering and a short section of newly forming myelin.
MS study: Metformin-treated cells aided repair in mice

11/16/2026

In mice with damaged nerve coverings, fat-derived stem cells treated with metformin improved repair.

Read More
Two navy brain silhouettes with matching fold patterns sit side by side, loosely connected by a thread on cream.
Inherited brain structure patterns linked to MS risk

11/17/2026

Genetic and brain scan data linked inherited brain structure patterns to MS risk. Researchers also f

Read More
Navy nerve-like lines meet at a central junction, with gaps in their ochre protective sleeves.
MS tissue and mice show damage in a brain vision hub

11/17/2026

Donated MS brain tissue showed damage in a vision hub. Mouse findings linked local immune cell activ

Read More
Two views of spinal cord nerve endings, with fewer chemical particles around the endings on the right.
Lab drug cut chemical release in MS-like mouse tissue

11/15/2026

In tissue from mice with an MS-like disease, a lab drug reduced excess chemical release from nerve e

Read More

Not all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.